Nuveen
ZVRA icon

Nuveen’s Zevra Therapeutics ZVRA Stock Holding History

Nuveen’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
166,171
-26,417
-14% -$294K ﹤0.01% 2486
2026
Q1 		$1.79M Buy
192,588
+49,456
+35% +$446K ﹤0.01% 2317
2025
Q4 		$1.28M Sell
143,132
-9,900
-6% -$93.6K ﹤0.01% 2490
2025
Q3 		$1.46M Buy
153,032
+9,900
+7% +$99.3K ﹤0.01% 2437
2025
Q2 		$1.26M Buy
143,132
+28,198
+25% +$229K ﹤0.01% 2505
2025
Q1 		$6.65M Sell
114,934
-38,143
-25% -$303K ﹤0.01% 1775
2024
Q4 		$1.28M Sell
153,077
-74,087
-33% -$632K ﹤0.01% 2597
2024
Q3 		$1.58M Buy
227,164
+97,434
+75% +$661K ﹤0.01% 2539
2024
Q2 		$636K Hold
129,730
– – ﹤0.01% 2914
2024
Q1 		$752K Hold
129,730
– – ﹤0.01% 2816
2023
Q4 		$850K Hold
129,730
– – ﹤0.01% 2805
2023
Q3 		$625K Hold
129,730
– – ﹤0.01% 2766
2023
Q2 		$662K Buy
+129,730
New +$699K ﹤0.01% 2839
2022
Q2 		– Sell
-101,793
Closed -$516K – 3512
2022
Q1 		$516K Buy
101,793
+1,566
+2% +$9.96K ﹤0.01% 3008
2021
Q4 		$748K Sell
100,227
-6,813
-6% -$60.8K ﹤0.01% 2953
2021
Q3 		$972K Sell
107,040
-3,677
-3% -$37.1K ﹤0.01% 2994
2021
Q2 		$1.42M Buy
+110,717
New +$1.19M ﹤0.01% 2865

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's ZVRA Position: Q2 2026 in Review

Nuveen reduced its Zevra Therapeutics (ZVRA) stake by 14% in Q2 2026, selling an estimated $294K and leaving 166,171 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

Nuveen first reported a position in ZVRA in Q2 2021 and has held it in 17 quarters since. The position peaked at $6.65M in Q1 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Nuveen held 166,171 shares of Zevra Therapeutics worth $2.38M as of Q2 2026.
  • Nuveen sold 26,417 Zevra Therapeutics shares in Q2 2026, an estimated $294K.
  • Zevra Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2486 holding.
  • Nuveen first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Nuveen's Zevra Therapeutics position peaked at $6.65M in Q1 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.